Isoquinoline Derivative Composition for Low-Toxicity Mitophagy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods to induce mitophagy activity, such as CCCP, FCCP, and rotenone, are toxic and cannot be used as drugs due to their strong cytotoxicity, limiting their application in promoting mitophagy for preventing or treating diseases caused by mitochondrial dysfunction.
Innovation Solution
A pharmaceutical and food composition comprising isoquinoline derivative compounds or their salts are developed to promote mitophagy activity, increase mitophagy in cells, and inhibit mitochondrial dysfunction without causing cellular toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If mitochondrial toxins (CCCP, FCCP, rotenone) are used to induce mitophagy activity, then mitophagy activity is enhanced, but cellular toxicity increases
Solution Approach 1:
The patent modifies the chemical structure of isoquinoline derivatives by changing parameters such as substituting hydrogen atoms at specific positions (e.g., positions 3, 4, or 6) with various functional groups (halogen, alkyl, aryl, heteroaryl, etc.). This structural parameter change allows the compounds to induce mitophagy activity while reducing cellular toxicity, as demonstrated by the reduced cytotoxicity compared to conventional mitochondrial toxins.
Solution Approach 2:
The patent creates composite molecular structures by combining isoquinoline core structures with various substituent groups (halogen, alkyl, aryl, heteroaryl, etc.). These composite isoquinoline derivative compounds achieve a balance between mitophagy induction and toxicity reduction, making them suitable for therapeutic applications where conventional toxins fail due to excessive cytotoxicity.
2Reliability
If conventional mitochondrial toxins are used to promote mitophagy, then damaged mitochondria are removed, but the compounds cannot be used as drugs due to strong cytotoxicity
Solution Approach 1:
The patent applies local quality modification by introducing specific functional groups at specific positions of the isoquinoline molecule. For example, substituting hydrogen at position 3, 4, or 6 with halogen, alkyl, aryl, or heteroaryl groups creates localized chemical modifications that selectively enhance mitophagy activity while reducing overall cytotoxicity. This localized modification approach allows the compound to be effective as a drug.
Solution Approach 2:
The patent develops novel isoquinoline derivatives that can be administered as therapeutic agents, replacing the need for persistent toxic mitochondrial toxins. These compounds provide a temporary, controlled mitophagy induction effect without the long-term toxic accumulation issues of conventional toxins like CCCP and FCCP, making them suitable for clinical use.
Data Source
AI summary
The present disclosure relates to novel isoquinoline derivatives. The derivatives have an effect of promoting mitophagy activity, thereby reducing mitochondria with structural and/or functional damage. In particular, the novel isoquinoline derivatives according to the present disclosure do not induce mitochondrial dysfunction and have been identified as safe compounds that are non-toxic to cells, and thus can be utilized for the prevention, amelioration, and/or treatment of various diseases that may be caused by abnormal mitochondria.